Biogen, Genentech amend deal on MS drug

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

Biogen, Genentech amend deal on MS drug

Postby MSUK » Thu Oct 21, 2010 10:45 pm

Image

Biogen Idec Inc. and Genentech said Thursday they amended their development agreement on a potential multiple sclerosis treatment.
Genentech, a unit of Swiss drug developer Roche, will now have responsibility for the further development of ocrelizumab in multiple sclerosis and will fund all the costs going forward.

Biogen will receive tiered, double-digit royalties on U.S. sales that will approximate its current 30 percent interest in the compound........... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1397
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 2212
Joined: Wed Oct 14, 2009 2:00 pm

Advertisement

Return to General Discussion

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users


Contact us | Terms of Service